Parker Waichman LLP

J&J To Add Warning To Drug

  J&J Add Warning To Drug Label. Johnson & Johnson said Monday that it asked European regulators to add a warning to the label of its biotech anemia drug, a move that could benefit a rival product from Amgen Inc. J&J said that the label should warn kidney disease patients not to take Eprex by […]

Warning To Drug

 

J&J Add Warning To Drug Label. Johnson & Johnson said Monday that it asked European regulators to add a warning to the label of its biotech anemia drug, a move that could benefit a rival product from Amgen Inc.

J&J said that the label should warn kidney disease patients not to take Eprex by injection into the skin but by intravenous infusion. About 160 European patients who used the drug developed a rare condition called pure red cell aplasia, in which the body loses its ability to make red blood cells. Patients depend on blood transfusions to survive.

Nearly all patients who developed the condition received Eprex by injection.

J&J said it reached the decision about the label change after consulting with French authorities. European Union regulators have 24 hours to comment on the label change, which could drive a portion of Eprex’s $1 billion in sales to Amgen or Swiss drug maker Roche Group.

Eprex is a synthetic version of erythropoietin, or EPO, the protein that spurs red blood cell production. J&J sells it in Europe under an exclusive license from Thousand Oaks-based Amgen, which markets its own version of EPO to dialysis patients in the United States.

Analysts said Amgen’s drug Aranesp, a modified version of EPO, could get a lift from J&J’s woes. Aranesp, launched a year ago, is more costly than Eprex. But less medication is needed when the drugs are taken by injection. So injectable Aranesp compares favorably with intravenous Eprex, Amgen says.

Concerns in Europe are Linked to Formulation Changes

The concerns in Europe are linked to formulation changes in J&J’s Eprex, and that formula is not marketed in the U.S.

J&J closed at $55.70, down $1.32 on the New York Stock Exchange. Amgen closed at $48.57, up $1.37 on Nasdaq.

Also on Monday, Amgen said that it could provide Enbrel to all patients on a waiting list for the rheumatoid arthritis drug, which has been in short supply since last December.

The company said it was too soon to know how many of the 40,000 patients on the list still want Enbrel, the crown jewel of Amgen’s $9.6-billion purchase of Immunex Corp. Many patients switched to competing prescription medications during the firms’ production problems.

Amgen said the announcement is not related to the completion of a Rhode Island factory that should double Enbrel supplies. Amgen expects regulatory approval of the facility by early next year, just as a rival drug from Abbott Laboratories is expected to reach the market.

Need Legal Help Regarding Warning To Drug?

The personal injury attorneys at Parker Waichman LLP offer free, no-obligation case evaluations. For more information, fill out our online contact form or call 1-800-YOURLAWYER (1-800-968-7529).

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Excellent service
Cris Valdueza
6 years ago
5 Star Reviews 150
I am a 911 first responder.iwas at the end of my rope feeling hopeless ! After speaking with Parker and waickman.i had a paralegal Ashley Lopilato Hanging my case .she was there for me every step of the way .from start To finish.even during my battle with cancer and 3 surgeries.for legal and moral support In my opinion she will make an excellent litagaor one day and be an asset to any firm . We met the other day after countless phone calls .and needless to say she immediately Made me feel like I was in good Hands ! BRAVO Ashley And a special thanks to Gina viti .thank you ladies for always giving me hope And my future to look forward for thanks to you . With my warmest regards Joe ader
joseph ader
3 years ago
5 Star Reviews 150
I am very grateful to the Waichman LLP law firm for all their help throughout the process. In my case, they were very kind, especially my friend Jorge Peniche, who was very attentive to my case. I am more satisfied with the final decision in my case. Thank you very much.
Silverwolf Romano
a year ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038